| Bioactivity | Dofequidar sesquifumarate (MS-209) is a novel quinoline compound, which can reverse P-glycoprotein (P-gp)-mediated MDR[1]. |
| CAS | 158681-49-3 |
| Formula | C30H31N3O3.3/2C4H4O4 |
| Molar Mass | 1311.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Naito M, et al. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res. 2002 Feb;8(2):582-8. [2]. Nokihara H, et al. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells. Jpn J Cancer Res. 2001 Jul;92(7):785-92. [3]. Nakanishi O, et al. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncol Res. 1997;9(2):61-9. |
Dofequidar sesquifumarate
CAS: 158681-49-3 F: C30H31N3O3.3/2C4H4O4 W: 1311.39
Dofequidar sesquifumarate (MS-209) is a novel quinoline compound, which can reverse P-glycoprotein (P-gp)-mediated MDR.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.